THIOHYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE
Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of histone deacetylase. Also described herein are methods of using such HDAC inhibitors, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of HDAC activity.
1 . A compound of Formula (IIa):
wherein:
Y is alkylene optionally substituted with cycloalkyl, optionally substituted phenyl, alkylthio, alkylsulfinyl, alkysulfonyl, optionally substituted phenylalkylthio, optionally substituted phenylalkylsulfonyl, hydroxy, or optionally substituted phenoxy;
R 3 is hydrogen, alkyl, hydroxyalkyl, or optionally substituted phenyl; and
Ar 2 is aryl, aralkyl, aralkenyl, heteroaryl, heteroaralkyl, heteroaralkenyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, or heterocycloalkylalkyl, where Ar 2 is substituted or unsubstituted; or
a pharmaceutically acceptable salt thereof.
2 . The compound of claim 1 , wherein:
R 3 is hydrogen; methyl; ethyl; propyl; butyl; i-propyl; 2-hydroxy-ethyl; phenyl; or benzyl.
3 . The compound of claim 2 , wherein:
Y is —CH 2 —CH 2 —; —CH 2 —CH(CH 3 )—; —CH(CH 3 )—CH 2 —; —CH(CH 2 CH 3 )—CH 2 —; —CH(i-propyl)-CH 2 —; —CH(i-butyl)-CH 2 —; —CH(n-butyl)-CH 2 —; —CH(cyclohexyl-methyl)-CH 2 —; —CH(benzyl)-CH 2 —; —CH(2-phenylethyl)-CH 2 —; —CH(benzylS-methyl)-CH 2 —; —CH(benzylSO 2 -methyl)-CH 2 —; —CH(2-MeS-ethyl)-CH 2 —; —CH(hydroxy-methyl)-CH 2 —; —CH(2-MeSO 2 -ethyl)-CH 2 —; —CH(4-Cl-benzyl)-CH 2 —; —CH(benzyl-S-methyl)-CH 2 —; —CH(phenyl)-CH 2 —; —CH(benzylSO 2 -methyl)-CH 2 —; —CH 2 —CH 2 —CH 2 —; —CH(CH 3 Smethyl)-CH 2 —; —CH(CH 3 SO 2 -methyl)-CH 2 —; or —CH 2 CH-(phenoxymethyl)-.
4 . The compound of claim 3 , wherein:
Ar 2 is heteroaryl optionally substituted with one or two substituents independently selected from alkyl, halo, haloalkyl, alkoxy, alkoxyalkyl, hydroxyalkoxy, hydroxyalkoxyalkyl, alkoxyalkyloxy, alkoxyalkyloxyalkyl, aminoalkyl, aminoalkoxy, haloalkoxy, haloalkoxyalkyl, optionally substituted phenylalkyl, optionally substituted phenyloxyalkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyloxy, optionally substituted heteroaryloxyalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted heterocycloalkyloxy, optionally substituted heterocycloalkylalkyloxy, -alkylene-S(O)nR a (where n is 0, 1, or 2; and R a is hydroxyalkyl or optionally substituted phenyl), -alkylene-NR c -alkyleneCONR c R d (where R c is hydroxyl and R d and R e are independently hydrogen or alkyl), -alkylene-N(heteroalkyl) 2 , or carboxyalkylaminoalkyl.
5 . The compound of claim 4 , wherein:
Ar 2 is thien-2-yl, pyridin-3-yl, quinolin-6-yl, benzothiazol-2-yl, benzoxazol-2-yl, benzofuran-2-yl, benzofuran-5-yl, benzothien-2-yl, furan-2-yl, 1H-benzimidazol-2-yl, 1H-pyrrol-2-yl, thiazol-2-yl, 1H-indol-2-yl, 1H-indol-5-yl, 1H-indol-3-yl, quinolin-3-yl, quinolin-8-yl, 1H-indazol-3-yl, 1H-benzotriazol-5-yl, isoquinolin-1-yl, isoquinolin-3-yl, quinoxalin-2-yl, quinolin-2-yl, 1H-benzimidazol-5-yl, quinolin-1-yl, pyridin-2-yl, quinolin-2-yl, furan-3-yl, or thien-3-yl, wherein Ar 2 is optionally substituted with one or two substituents selected from among alkyl, halo, haloalkyl, alkoxy, alkoxyalkyl, hydroxyalkoxy, hydroxyalkoxyalkyl, alkoxyalkyloxy, alkoxyalkyloxyalkyl, aminoalkyl, aminoalkoxy, haloalkoxy, haloalkoxyalkyl, optionally substituted phenylalkyl, optionally substituted phenyloxyalkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyloxy, optionally substituted heteroaryloxyalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted heterocycloalkyloxy, optionally substituted heterocycloalkylalkyloxy, -alkylene-S(O)nR a (where n is 0, 1, or 2; and R 1 is hydroxyalkyl or optionally substituted phenyl), -alkylene-NR-alkyleneCONR c R d (where R c is hydroxyl and R d and R e are independently hydrogen or alkyl), -alkylene-N(heteroalkyl) 2 , and carboxyalkylaminoalkyl.
6 . A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable excipient.
7 . A method for treating cancer which method comprises administering to the animal a pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable excipient in combination with one or more compound(s) independently selected from an estrogen receptor modulator, an androgen receptor modulator, retinoid receptor modulator, a cytotoxic agent, another antiproliferative agent, a prenyl-protein transferase inhibitor, an HMG-CoA reductase inhibitor, an HIV protease inhibitor, a reverse transcriptase inhibitor, or an angiogenesis inhibitor.
8 . A 1,3-disubstituted-1H-indole-6-thiohydroxamic acid compound, wherein the substituent at the 1-position is —X 2 —R 2 and the substituent at the 3-position is R 3 , wherein:
X 2 is a bond, or a substituted or unsubstituted group selected from among C 1 -C 6 alkylene, C 2 -C 6 alkenylene, C 2 -C 6 alkynylene, C 1 -C 6 -fluoroalkylene, C 2 -C 6 -fluoroalkenylene, C 1 -C 6 haloalkylene, C 2 -C 6 haloalkenylene, C 1 -C 6 heteroalkylene; C(═O)—, and C(═O)—C 1 -C 6 alkylene;
R 2 is a substituted or unsubstituted group selected from among aryl, heteroaryl, cycloalkyl, and heterocycloalkyl;
where if R 2 is substituted, then each substituent on R 2 is selected from among hydrogen, halogen, —CN, —NO 2 , —S(═O) 2 NH 2 , —CO 2 H, —CO 2 R 10 , —C(═O)R 11 , —S—R 11 , —S(═O)—R 11 , —S(═O) 2 —R 11 , —NR 10 C(═O)—R 11 , —C(═O)N(R 10 ) 2 , —S(═O) 2 N(R 10 ) 2 , —NR 10 S(═O) 2 —R 11 , —OC(═O)N(R 10 ) 2 , —NR 10 C(═O)O—R 11 , —OC(═O)O—R 11 , —NHC(═O)NH—R 11 , —OC(═O)—R 11 ; —N(R 10 ) 2 , substituted or unsubstituted C 1 -C 6 alkyl, C 1 -C 6 -fluoroalkyl, substituted or unsubstituted C 2 -C 6 alkenyl, substituted or unsubstituted C 2 -C 6 alkynyl, substituted or unsubstituted C 1 -C 6 alkoxy, C 1 -C 6 fluoroalkoxy, substituted or unsubstituted C 1 -C 6 heteroalkyl, substituted or unsubstituted C 3 -C 8 cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;
R 10 is hydrogen, or a substituted or unsubstituted group selected from among C 1 -C 6 alkyl, C 1 -C 6 fluoroalkyl, C 1 -C 6 heteroalkyl, C 3 -C 8 cycloalkyl, C 2 -C 8 heterocycloalkyl, aryl, and heteroaryl;
R 11 is a substituted or unsubstituted group selected from among C 1 -C 6 alkyl, C 1 -C 6 fluoroalkyl, C 3 -C 8 cycloalkyl, C 2 -C 8 heterocycloalkyl, aryl, and heteroaryl;
R 3 is hydrogen, halogen, substituted or unsubstituted C 1 -C 6 alkyl, substituted or unsubstituted C 2 -C 6 alkenyl, substituted or unsubstituted C 2 -C 6 alkynyl, substituted or unsubstituted C 1 -C 6 alkoxy, substituted or unsubstituted C 1 -C 6 fluoroalkoxy, substituted or unsubstituted C 1 -C 6 heteroalkyl, substituted or unsubstituted phenyl, or —X 6 —R 6 ;
X 6 is a C 1 -C 6 alkylene, C 1 -C 6 fluoroalkylene, C 2 -C 6 alkenylene, C 2 -C 6 heteroalkylene;
R 6 is hydrogen, halogen, —CN, hydroxy, amino, C 1 -C 6 alkylamino, di(C 1 -C 6 alkyl)amino, C 1 -C 6 alkoxy, C 3 -C 8 cycloalkyl, C 2 -C 8 heterocycloalkyl, phenyl, heteroaryl, or X 7 —R 7
X 7 is a bond, —O—, —S—, —S(═O)—, —S(═O) 2 —, —NR a —, —C(═O)—, —C(═O)O—, —OC(═O)—, —NHC(═O)—, —C(═O)NR a —, —S(═O) 2 NR a —, —NHS(═O) 2 —, —OC(═O)NR a —, —NHC(═O)O—, —OC(═O)O—, —NHC(═O)NR a —;
R 7 is hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 1 -C 6 heteroalkyl, C 1 -C 6 haloalkyl, C 3 -C 8 cycloalkyl, cycloalkylalkyl, C 2 -C 8 heterocycloalkyl, heterocycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,
R a is selected from among hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, hydroxy, C 1 -C 6 alkoxy, C 1 -C 6 fluoroalkoxy, C 1 -C 6 heteroalkyl; or
R a and R 7 together with the N atom to which they are attached form a 5-, 6-, or 7-membered heterocycloalkyl;
or an active metabolite, pharmaceutically acceptable solvate, pharmaceutically acceptable salt, pharmaceutically acceptable N-oxide, or pharmaceutically acceptable prodrug thereof.
9 . The compound of claim 8 , wherein:
X 2 is a substituted or unsubstituted group selected from among C 1 -C 6 alkylene, C 2 -C 6 alkenylene, C 1 -C 6 fluoroalkylene, C 2 -C 6 fluoroalkenylene, and C 1 -C 6 heteroalkylene.
10 . The compound of claim 9 , wherein:
R 2 is an optionally substituted group selected from among phenyl, naphthyl, monocyclic heteroaryl, bicyclic heteroaryl, C 3 -C 8 cycloalkyl, monocyclic heterocycloalkyl, and bicyclic heterocycloalkyl.
11 . The compound of claim 8 , wherein:
R 3 is hydrogen, halogen, substituted or unsubstituted C 1 -C 6 alkyl, substituted or unsubstituted C 2 -C 6 alkenyl, substituted or unsubstituted C 1 -C 6 heteroalkyl, substituted or unsubstituted phenyl, or —X 6 —R 6 ;
X 6 is a C 1 -C 6 alkylene, C 1 -C 6 fluoroalkylene, C 2 -C 6 alkenylene, or C 2 -C 6 heteroalkylene;
R 6 is hydrogen, halogen, —CN, hydroxy, amino, C 1 -C 6 alkylamino, di(C 1 -C 6 alkyl)amino, C 1 -C 6 alkoxy, C 3 -C 8 cycloalkyl, C 2 -C 8 heterocycloalkyl, phenyl, heteroaryl, or X 7 —R 7
X 7 is a bond, —O—, —S—, —S(═O)—, —S(═O) 2 —, —NR a —, —C(═O)—, —C(═O)O—, —OC(═O)—, —NHC(═O)—, —C(═O)NR a —, —S(═O) 2 NR a —, —NHS(═O) 2 —, —OC(═O)NR a —, —NHC(═O)O—, —OC(═O)O—, —NHC(═O)NR a —;
R 7 is hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 1 -C 6 heteroalkyl, C 1 -C 6 haloalkyl, C 3 -C 8 cycloalkyl, cycloalkylalkyl, C 2 -C 8 heterocycloalkyl, heterocycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,
R a is selected from among hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, hydroxy, C 1 -C 6 alkoxy, C 1 -C 6 fluoroalkoxy, C 1 -C 6 heteroalkyl; or
R a and R 7 together with the N atom to which they are attached form a 5-, 6-, or 7-membered heterocycloalkyl
12 . The compound of claim 8 , wherein the compound is a selective histone deacetylase 8 (HDAC8) inhibitor.
13 . The compound of claim 12 , wherein the selective HDAC8 inhibitor has an IC 50 for histone deacetylase 8 activity that is at least 10 fold lower than the IC 50 of the selective HDAC8 inhibitor for activity of histone deacetylase 1, histone deacetylase 2, histone deacetylase 3, histone deacetylase 6, histone deacetylase 10, or histone deacetylase 11.
14 . A pharmaceutical composition comprising a compound, pharmaceutically acceptable salt, pharmaceutically acceptable N-oxide, pharmaceutically active metabolite, pharmaceutically acceptable prodrug, or pharmaceutically acceptable solvate of claim 13 and a pharmaceutically acceptable diluent, excipient or binder.
15 . A method of treating T-cell lymphoma or leukemia in a subject in need thereof, comprising administering to the subject a pharmaceutical composition containing a therapeutically effective amount of a compound of claim 13 .
16 . A method of improving the pharmacokinetic properties of a hydroxamic acid HDAC inhibitor compound, wherein said method comprises replacing the hydroxamic acid functional group of the hydroxamic acid HDAC inhibitor compound with a thiohydroxamic functional group to provide a thiohydroxamic acid HDAC inhibitor compound.
17 . The method of claim 16 , wherein replacing the hydroxamic acid functional group of the hydroxamic acid HDAC inhibitor compound with a thiohydroxamic functional group to provide a thiohydroxamic acid HDAC inhibitor compound comprises:
a) synthesizing the carboxylic acid ester compound that is the final precursor compound to the hydroxamic acid HDAC inhibitor compound, wherein treatment of the carboxylic acid ester compound with hydroxylamine would provide the hydroxamic acid HDAC inhibitor compound;
b) treating the carboxylic acid ester compound of a) with P 4 S 10 , and hexamethyldisiloxane (HMDO) to obtain a carbothioester compound; and
c) reacting the carbothioester compound of b) with hydroxylamine to provide a thiohydroxamic acid HDAC inhibitor compound.